Abstract 1367P
Background
Cancers often exhibit sexual dimorphism. Yet, the impact of sex on patient and tumour characteristics as well as survival remains largely unexplored in advanced NSCLC following the introduction of immune checkpoint inhibitors and targeted therapies into routine clinical practice.
Methods
In this cohort study, we identified adults diagnosed with advanced NSCLC from January 1, 2017, to December 31, 2023, using Danish nationwide health registries and clinical databases. We compared females to males across demographic, social, socioeconomic, patient and tumour characteristics (including PDL-1 expression and driver mutations), treatments, and overall survival (OS) from diagnosis and from initiation of first line of treatment (LOT1). Cox proportional hazards regression modeling was employed, adjusting for key covariates in both the overall cohort and stratified by stage, histological subtype, PD-L1 expression level, and treatment type. Propensity score matching was conducted as a sensitivity analysis.
Results
Among 14,639 individuals, sex distribution was even, with males comprising 50% (n=7,325). Median OS from diagnosis was 8·8 months (95% confidence interval [CI] 8·4-9·2) for females and 7·0 months (95% CI: 6·7-7·3) for males, while from initiation of LOT1, median OS was 14·2 months (95% CI: 13·5-15·2) for females and 10·8 months (95% CI: 10·3-11·5) for males. Patient and tumour characteristics differed between sexes, however after adjustment the female-to-male mortality hazard ratio was 0·84 (95% CI: 0·81-0·88) from diagnosis and 0·80 (95% CI: 0·75-0·84) from initiation LOT1. Sex-differential mortality was also identified in stratification on most covariates.
Conclusions
This study significantly enhances our understanding of sex-based disparities in advanced NSCLC. The findings indicate a potential underlying biological sex difference with clinical and pharmacological implications, favoring longer survival in females. Our results underscore the critical role of acknowledging sex as a key variable in oncology trials, research and clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1362P - Evaluation of imaging-based prognostication (IPRO) for advanced non-small cell lung cancer (aNSCLC) using deep learning applied to computed tomography (CT)
Presenter: Omar Khan
Session: Poster session 06
1363P - An AI-derived tool to pre-screen lung cancer candidates for clinical trials
Presenter: Mihaela Aldea
Session: Poster session 06
1364P - Federated analysis of overall survival (OS) by location of metastases (mets) in patients (pts) with metastatic NSCLC (mNSCLC) from the Digital Oncology Network for Europe (DigiONE)
Presenter: Åsa Öjlert
Session: Poster session 06
1365P - Does cancer care differ for older adults with lung cancer living with and without Alzheimer disease and related dementias (ADRD)?
Presenter: Lorinda Coombs
Session: Poster session 06
1366P - Natural Language Processing (NLP) as promising artificial intelligence (AI) tool to improve patients (pts) enrollment in clinical trials (CT): Analysis in real-world conditions on a lung cancer cohort
Presenter: Julien Mazieres
Session: Poster session 06
1368P - Correlation between depth of response at 6 months and survival in patients (pts) with metastatic non-small cell lung carcinoma (mNSCLC): SPORE trial
Presenter: Fabien Moinard-Butot
Session: Poster session 06
1369P - Trilaciclib combined with intraventricular injection chemotherapy in the treatment of advanced NSCLC with leptomeningeal metastasis: A prospective, single-arm, phase II clinical trial
Presenter: Shen Cun Fang
Session: Poster session 06
1370P - Survival of de novo metastatic non-small cell lung cancer according to biomarker status in Denmark and Norway: A register-based cohort study
Presenter: Johan Liseth Hansen
Session: Poster session 06
1372P - Advanced non-small cell lung carcinoma in the era of immunotherapy: Survival and the risk of multiple primary malignancies
Presenter: Nahla Ali
Session: Poster session 06